Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors
Omeprazole is the first drug in this class. Since it was introduced in 1989, several other PPIs have emerged: lansoprazole, rabeprazole, and pantoprazole. Proton pump inhibitors are modified benzimidazoles with a pyridine ring, differing by virtue of substitutions on both rings (Fig 1). [...]omepraz...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2006-03, Vol.117 (3), p.707-708 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 708 |
|---|---|
| container_issue | 3 |
| container_start_page | 707 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 117 |
| creator | Pérez Pimiento, A.J. Prieto Lastra, L. Rodríguez Cabreros, M.I. González Sánchez, L.A. Mosquera, M. Rodríguez Cubero, A. García |
| description | Omeprazole is the first drug in this class. Since it was introduced in 1989, several other PPIs have emerged: lansoprazole, rabeprazole, and pantoprazole. Proton pump inhibitors are modified benzimidazoles with a pyridine ring, differing by virtue of substitutions on both rings (Fig 1). [...]omeprazole and pantoprazole have respectively a methoxy and a difluoromethoxy chain in their benzimidazole rings, whereas lansoprazole and rabeprazole have no modifications in that ring, but their pyridine rings have respectively a trifluoroethoxy and methoxypropoxy chain. |
| doi_str_mv | 10.1016/j.jaci.2005.11.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1504745253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674905025030</els_id><sourcerecordid>3238986591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-47723613f5b4cacca9f33fc6bf7cf63728c8eef68980d17af98672f96838f0a3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIwXNrPtokBS8ifoHgxXtI0wmbstvUJKusv94su-LN0zDwzDszD0KXBFcEE34zVIM2rqIYNxUhFcbkCM0JbkXJJW2O0RzjlpRc1O0MncU44Nwz2Z6iGeENpbXgc6SetxOECGN0yX26tC2SL1Z6jH4K-tuvoNBjXwTdwW__5dIyQysIejSww31aQiim4JMfi2mzngo3Ll3nkg_xHJ1YvYpwcagL9P748H7_XL6-Pb3c372WhjUklbUQlHHCbNPVRhujW8uYNbyzwljOBJVGAlguW4l7IrRtJRfUtlwyabFmC3S9j81XfGwgJjX4TRjzRkUaXIu6oQ3LFN1TJvgYA1g1BbfWYasIVjulalA7pWqnVBGistI8dHWI3nRr6P9GDg4zcLsHIP_36SCoaBxkN70LYJLqvfsv_wd-IIl8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504745253</pqid></control><display><type>article</type><title>Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Pérez Pimiento, A.J. ; Prieto Lastra, L. ; Rodríguez Cabreros, M.I. ; González Sánchez, L.A. ; Mosquera, M. Rodríguez ; Cubero, A. García</creator><creatorcontrib>Pérez Pimiento, A.J. ; Prieto Lastra, L. ; Rodríguez Cabreros, M.I. ; González Sánchez, L.A. ; Mosquera, M. Rodríguez ; Cubero, A. García</creatorcontrib><description>Omeprazole is the first drug in this class. Since it was introduced in 1989, several other PPIs have emerged: lansoprazole, rabeprazole, and pantoprazole. Proton pump inhibitors are modified benzimidazoles with a pyridine ring, differing by virtue of substitutions on both rings (Fig 1). [...]omeprazole and pantoprazole have respectively a methoxy and a difluoromethoxy chain in their benzimidazole rings, whereas lansoprazole and rabeprazole have no modifications in that ring, but their pyridine rings have respectively a trifluoroethoxy and methoxypropoxy chain.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2005.11.001</identifier><identifier>PMID: 16522476</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adult ; Benzimidazoles - adverse effects ; Cross Reactions ; Drug dosages ; Drug Hypersensitivity - etiology ; Drug Hypersensitivity - immunology ; Drug therapy ; Enzyme Inhibitors - adverse effects ; Female ; Humans ; Lansoprazole ; Omeprazole - adverse effects ; Omeprazole - analogs & derivatives ; Proton Pump Inhibitors ; Rabeprazole ; Skin Tests</subject><ispartof>Journal of allergy and clinical immunology, 2006-03, Vol.117 (3), p.707-708</ispartof><rights>2006 American Academy of Allergy, Asthma and Immunology</rights><rights>Copyright Elsevier Limited Mar 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-47723613f5b4cacca9f33fc6bf7cf63728c8eef68980d17af98672f96838f0a3</citedby><cites>FETCH-LOGICAL-c351t-47723613f5b4cacca9f33fc6bf7cf63728c8eef68980d17af98672f96838f0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674905025030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16522476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez Pimiento, A.J.</creatorcontrib><creatorcontrib>Prieto Lastra, L.</creatorcontrib><creatorcontrib>Rodríguez Cabreros, M.I.</creatorcontrib><creatorcontrib>González Sánchez, L.A.</creatorcontrib><creatorcontrib>Mosquera, M. Rodríguez</creatorcontrib><creatorcontrib>Cubero, A. García</creatorcontrib><title>Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Omeprazole is the first drug in this class. Since it was introduced in 1989, several other PPIs have emerged: lansoprazole, rabeprazole, and pantoprazole. Proton pump inhibitors are modified benzimidazoles with a pyridine ring, differing by virtue of substitutions on both rings (Fig 1). [...]omeprazole and pantoprazole have respectively a methoxy and a difluoromethoxy chain in their benzimidazole rings, whereas lansoprazole and rabeprazole have no modifications in that ring, but their pyridine rings have respectively a trifluoroethoxy and methoxypropoxy chain.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adult</subject><subject>Benzimidazoles - adverse effects</subject><subject>Cross Reactions</subject><subject>Drug dosages</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Drug Hypersensitivity - immunology</subject><subject>Drug therapy</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Omeprazole - adverse effects</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Proton Pump Inhibitors</subject><subject>Rabeprazole</subject><subject>Skin Tests</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6BzxIwXNrPtokBS8ifoHgxXtI0wmbstvUJKusv94su-LN0zDwzDszD0KXBFcEE34zVIM2rqIYNxUhFcbkCM0JbkXJJW2O0RzjlpRc1O0MncU44Nwz2Z6iGeENpbXgc6SetxOECGN0yX26tC2SL1Z6jH4K-tuvoNBjXwTdwW__5dIyQysIejSww31aQiim4JMfi2mzngo3Ll3nkg_xHJ1YvYpwcagL9P748H7_XL6-Pb3c372WhjUklbUQlHHCbNPVRhujW8uYNbyzwljOBJVGAlguW4l7IrRtJRfUtlwyabFmC3S9j81XfGwgJjX4TRjzRkUaXIu6oQ3LFN1TJvgYA1g1BbfWYasIVjulalA7pWqnVBGistI8dHWI3nRr6P9GDg4zcLsHIP_36SCoaBxkN70LYJLqvfsv_wd-IIl8</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Pérez Pimiento, A.J.</creator><creator>Prieto Lastra, L.</creator><creator>Rodríguez Cabreros, M.I.</creator><creator>González Sánchez, L.A.</creator><creator>Mosquera, M. Rodríguez</creator><creator>Cubero, A. García</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20060301</creationdate><title>Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors</title><author>Pérez Pimiento, A.J. ; Prieto Lastra, L. ; Rodríguez Cabreros, M.I. ; González Sánchez, L.A. ; Mosquera, M. Rodríguez ; Cubero, A. García</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-47723613f5b4cacca9f33fc6bf7cf63728c8eef68980d17af98672f96838f0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adult</topic><topic>Benzimidazoles - adverse effects</topic><topic>Cross Reactions</topic><topic>Drug dosages</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Drug Hypersensitivity - immunology</topic><topic>Drug therapy</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Omeprazole - adverse effects</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Proton Pump Inhibitors</topic><topic>Rabeprazole</topic><topic>Skin Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez Pimiento, A.J.</creatorcontrib><creatorcontrib>Prieto Lastra, L.</creatorcontrib><creatorcontrib>Rodríguez Cabreros, M.I.</creatorcontrib><creatorcontrib>González Sánchez, L.A.</creatorcontrib><creatorcontrib>Mosquera, M. Rodríguez</creatorcontrib><creatorcontrib>Cubero, A. García</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez Pimiento, A.J.</au><au>Prieto Lastra, L.</au><au>Rodríguez Cabreros, M.I.</au><au>González Sánchez, L.A.</au><au>Mosquera, M. Rodríguez</au><au>Cubero, A. García</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>117</volume><issue>3</issue><spage>707</spage><epage>708</epage><pages>707-708</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Omeprazole is the first drug in this class. Since it was introduced in 1989, several other PPIs have emerged: lansoprazole, rabeprazole, and pantoprazole. Proton pump inhibitors are modified benzimidazoles with a pyridine ring, differing by virtue of substitutions on both rings (Fig 1). [...]omeprazole and pantoprazole have respectively a methoxy and a difluoromethoxy chain in their benzimidazole rings, whereas lansoprazole and rabeprazole have no modifications in that ring, but their pyridine rings have respectively a trifluoroethoxy and methoxypropoxy chain.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>16522476</pmid><doi>10.1016/j.jaci.2005.11.001</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2006-03, Vol.117 (3), p.707-708 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_journals_1504745253 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adult Benzimidazoles - adverse effects Cross Reactions Drug dosages Drug Hypersensitivity - etiology Drug Hypersensitivity - immunology Drug therapy Enzyme Inhibitors - adverse effects Female Humans Lansoprazole Omeprazole - adverse effects Omeprazole - analogs & derivatives Proton Pump Inhibitors Rabeprazole Skin Tests |
| title | Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T10%3A00%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypersensitivity%20to%20lansoprazole%20and%20rabeprazole%20with%20tolerance%20to%20other%20proton%20pump%20inhibitors&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=P%C3%A9rez%20Pimiento,%20A.J.&rft.date=2006-03-01&rft.volume=117&rft.issue=3&rft.spage=707&rft.epage=708&rft.pages=707-708&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2005.11.001&rft_dat=%3Cproquest_cross%3E3238986591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504745253&rft_id=info:pmid/16522476&rft_els_id=S0091674905025030&rfr_iscdi=true |